Skip to main content
TipRanks
Go Ultimate75% OFF

Revolution Medicines (42Z) AI Stock Analysis

17 Followers
DE:42Z

Revolution Medicines

(XETRA:42Z)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
FDA-approved commercial productFDA approval converts RVMD from a clinical-stage developer into a commercial oncology company with an approved oral therapy. The initial revenue base and prescription access create a durable platform for patient uptake, real-world evidence, and expansion into additional indications.
Negative Factors
Heavy cash burnThe scale of negative operating and free cash flow shows that current commercial revenue does not yet cover development and operating needs. Continued cash burn can increase financing dependence and reduce flexibility if the company’s pipeline or launch economics develop more slowly.

Revolution Medicines (42Z) vs. iShares MSCI Germany ETF (EWG)

-50%0%50%100%150%200%DE:42Z+128.52%EWG+6.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 34.57B
Dividend Yield
―
Average Volume (3M)
283
Price to Earnings (P/E)
-17.5
Beta (1Y)
0.80
Revenue Growth
―
EPS Growth
-67.73%
Country
Germany
Employees
883
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Revolution Medicines Business Overview & Revenue Model

Company Description

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug c...

Revolution Medicines Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-16.21%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentPositive

The call was strongly positive, driven by FDA approval, a rapid initial U.S. launch generating $198 million in revenue from more than 5 thousand commercial patients, broad early physician and payer access, positive regulatory progress in Europe, and continued advancement across pancreatic, lung, colorectal, and earlier-stage RAS(ON) programs. The principal challenges were that launch revenue includes finite early cohorts, normalized demand remains uncertain, formal payer policies are still developing, European approval is pending, and expenses and net loss increased substantially. Overall, the number and significance of the achievements materially outweighed the stated challenges.

Positive Updates

FDA Approval and U.S. Launch of RasOnQ
The FDA approved RasOnQ (Daraxonrasib) on August 26 for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or who are not candidates for multi-agent systemic therapy. The company immediately began making the oral targeted medicine available by prescription in the United States.

Negative Updates

Launch Revenue Includes Finite Early-Launch Dynamics
Management cautioned that the expanded access program transition and the initial cohort of patients who had exhausted available treatment options are finite early-launch dynamics. As the launch matures, revenue will increasingly reflect ongoing treatment for newly eligible patients and treatment duration, and management said it is too early to draw conclusions about the normalized launch trajectory.

Company Guidance

The company reiterated guidance for full year 2026 GAAP operating expenses of $2.1 billion to $2.2 billion, including expected noncash stock based compensation expense of $270 million to $290 million, and said full year 2027 GAAP operating expenses are expected to increase from the current GAAP operating expense run rate, with no specific range provided; it expects to manage channel inventory at approximately 2 weeks over the long run, while the quarter ended with less than 2 weeks of inventory, and expects the gross to net discount to increase within the anticipated 20% to 30% range; global enrollment in RASolute 303 is expected to complete in the first half of 2027, the initial phase 3 readout for RASolve 301 is planned in 2027, initial clinical monotherapy data for RMC-7 are expected in 2027, RM-005 remains on track for initiation of its first in human clinical study in the fourth quarter, and the company expects to provide a colorectal cancer clinical data update in the first half of 2027.

Revolution Medicines Risk Analysis

Revolution Medicines disclosed 86 risk factors in its most recent earnings report. Revolution Medicines reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our outstanding warrants may expire worthless or result in dilution, and may be redeemed on terms that are disadvantageous to warrant holders.Q3, 2026
2.We only recently began generating revenue from product sales and may never be profitable.Q3, 2026
3.Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the 2033 Notes and the Term Loan Facility.Q3, 2026

Revolution Medicines Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:42Z against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
EXELEXEL81Outperform$16.71B19.7945.54%―9.12%40.53%
INCYINCY73Outperform$24.27B56.097.11%―24.88%-65.67%
GMABGMAB63Neutral$30.80B43.2112.26%―19.61%-50.40%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BNTXBNTX49Neutral$21.04B-12.92-8.09%―-20.72%-160.57%
RLAYRLAY44Neutral$3.65B-10.93-40.25%―23.86%13.76%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%200%DE:42ZEXELINCYGMABBNTXRLAYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:42Z and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:42ZRevolution Medicines, Inc.146.2583.75134.00%
EXELExelixis68.2925.7860.64%
INCYIncyte117.8015.7415.42%
GMABGenmab (Otc)50.9720.5267.39%
BNTXBiontech Se Sponsored Adr83.26-12.33-12.90%
RLAYRelay Therapeutics Inc16.519.74143.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.